ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NMTC / earnings
AEMD (36) PLSM (47) FEMY (30) ICU (31) ⌘ Pro Terminal →

NeuroOne Medical Technologies Corporation (NMTC) Next Earnings Date & Expected ±12.5% Move

$0.93 +0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.93

NeuroOne Medical Technologies Corporation (NMTC) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $8.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NMTC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NMTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.93 (+0.82% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NMTC ranks #700 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NMTC compare to AEMD and PLSM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.7M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NMTC?
▼

Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.93 (-0.04%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (8)Whales (3)SEC (11)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$6 Bull$1 Base$1 Bear
📬 FREE NMTC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NMTC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY NMTC SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$1.10-10.9% Next Q
Q2 (-2Q)
38
Grade E$0.98-13.3% Next Q
Q3 (-1Q)
36
Grade E$0.85+9.4% Next Q
Current
33
Grade E$0.93-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NMTC Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NMTC currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.28) and Max Pain ($0.98) forces dealer call-delta covering toward $6.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NMTC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NMTC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 29, 2026 (~55 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.12 Expected Swing
$1.00 (-12.5%)Spot $0.93$1.05 (+12.5%)
MODEL EARNINGS SETUP GAUGE

NMTC Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: 163.5%

Model Bullish Setup (33/100)Model Risk Weight (67/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-09-30$9.1M-$3.6M-$2.9M56.5%
FY 20242024-09-30$3.5M-$12.3M-$11.1M31.3%
FY 20232023-09-30$2.0M-$11.9M-$12.9M56.5%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NMTC)

  • ✓Walkthrough of NMTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NMTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.29%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.97H $0.97L $0.93C $0.93VOL 33.8K
RES: $2.64SUP: $0.70SMA50: $1.28SMA200: $3.16
$5.16$3.97$2.78$1.59$0.40RES $2.64SUP $0.70$0.932026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NMTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NMTC Butterfly Map → + Track NMTC →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +163.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NMTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NMTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NMTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NMTC)

Health Care Rank #700 of 1015 ⚔️ AEMD vs NMTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NMTC vs. AEMD, PLSM, FEMY, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NeuroOne Medical Technologies Corporation (NMTC) ranks #700 by composite RQD confidence (33/100, grade E) and #906 by equity capitalization ($8.4M). Within this direct 5-issuer industry benchmark cohort, NMTC leads on earnings valuation at N/A trailing P/E, while NMTC leads on capital efficiency and profitability with -35.0% ROIC and 56.5% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with NMTC at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NMTC ACTIVE
NeuroOne Medical Technologies Corporation
E 33/100 — 56.5% -35.0% +0.82% $8.4M Benchmark Subject
AEMD
Aethlon Medical Inc.
D- 36/100 — — -35.0% -2.76% $8.7M /aemd-vs-nmtc →
PLSM
Pulsenmore Ltd.
D 47/100 — — — -1.87% $10.9M /plsm-vs-nmtc →
FEMY
Femasys Inc.
E 30/100 — 62.0% -35.0% -3.65% $11.5M /femy-vs-nmtc →
ICU
SeaStar Medical Holding Corporation
E 31/100 — 95.7% -35.0% -2.23% $11.8M /icu-vs-nmtc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001500198 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), NeuroOne Medical Technologies Corporation (NMTC) reported GAAP revenue of $9.1M (+163.5% vs. FY2024 revenue of $3.5M , and +366.0% cumulative change since FY2023) , GAAP net income of -$3.6M, operating cash flow of -$2.8M, and free cash flow of -$2.9M (+73.8% YoY). On the balance sheet, NMTC closed FY2025 with $8.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $9.1M -$3.6M -$2.8M -$2.9M $8.6M —
FY2024 (FY) 2024-09-30 $3.5M -$12.3M -$11.0M -$11.1M $6.5M —
FY2023 (FY) 2023-09-30 $2.0M -$11.9M -$12.9M -$12.9M — —

3. NMTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NMTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.93 (+0.82% 1D, market cap $8.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NMTC ranks #700 in composite RQD confidence.

How does NMTC compare to AEMD and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NMTC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.5%, and ROIC of -35.0%. By comparison, AEMD (Aethlon Medical Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $8.7M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, NMTC leads on earnings multiple (N/A) while NMTC leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NMTC?

Per NMTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001500198), NeuroOne Medical Technologies Corporation generated $9.1M in revenue (+163.5% YoY), -$3.6M in net income, and -$2.9M in free cash flow against $8.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NMTC trading relative to its 50-day, 200-day, and 52-week technical levels?

NMTC last traded at $0.93 (+0.82% on volume of 12,664 shares), positioning the stock -27.34% below its 50-day simple moving average ($1.28) and -70.57% below its 200-day simple moving average ($3.16). Across its 52-week range of $0.77 to $6.12, NMTC sits at the 3.0% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.05).

Direct Sub-Reports: NMTC RQD Cockpit NMTC 12M Forecast NMTC Earnings & Move NMTC Dividends & DRIP NMTC Insiders & 13F NMTC Whale Options NMTC Profit Sankey NMTC News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

NMTC — NeuroOne Medical Technologies Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

NeuroOne Medical Technologies Corporation (NMTC) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.93 (+0.82% 1D, market capitalization $8.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 56.5%, operating margin of -46.5%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NeuroOne Medical Technologies Corporation is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..0B as presented in the profile field. Per the recent news wire, the company is associated with a brain drug-delivery platform that received a first order from a drugmaker, and a reported record $4.5 Million order.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), NeuroOne Medical Technologies Corporation (NMTC) reported $9.1M in annual revenue (up from $3.5M in FY2024, +163.5% YoY) and -$3.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.0M revenue, -$11.9M net income) through FY2025, NMTC scaled operating cash flow to -$2.8M and free cash flow to -$2.9M, backed by $8.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.77 – $6.12 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -46.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should monitor whether the drugmaker order relationship expands into recurring demand, since that would be the primary second-order dependency suggested by the news wire, but the graph does not map it.

  • Key Question #1: Can NMTC sustain or expand its -46.5% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.1M and free cash flow of -$2.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NMTC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NMTC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NeuroOne Medical Technologies Corporation (NMTC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NMTC Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NMTC Bull vs. Bear Conversation Board — What's Your Call at $0.93?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NMTC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NMTC:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.07 (+15.1%)
📌 Pinned Debate

Revenue grew from $2.0M in FY 2023 to $9.1M in FY 2025 and a Quiver Quantitative report cites a record $4.5 Million order topping guida

Revenue grew from $2.0M in FY 2023 to $9.1M in FY 2025 and a Quiver Quantitative report cites a record $4.5 Million order topping guidance.. When you look under the hood at NMTC, Fundamental Cash Engine is 8/20 with 56.5% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $6.12. My 12M target is $1.07.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 3/20 institutional whale-flow stock at $0.93 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.70 (-24.7%)
Spot @ $0.93

ROIC of -35%, operating margin of -46.5%, and an RQD score of 33 (E, Strong Sell) show persistent losses and weak institutional and ins

Here is the bear case nobody on the bull side wants to address on NMTC: ROIC of -35%, operating margin of -46.5%, and an RQD score of 33 (E, Strong Sell) show persistent losses and weak institutional and insider conviction.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%